The aim of our study was to compare the estrogen receptor, progesterone receptor and HER2 status as determined by the MapQuantTM test to the routine immuno-histochemical tests in early stage invasive breast cancer in a large comprehensive cancer center. This evidence concerns the gene ERBB2 and invasive breast carcinoma.